Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Jiangsu Hengrui Medicine Eyes Launch of 2-3 Generics in Japan Every Year: CEO
May 23, 2016
- Generic Makers Enjoy Revenue Rises as Govt Tailwinds Continue: Jiho Tally
May 23, 2016
- Chugai, Osaka Univ. Clinch 10 Billion Yen Immunology Pact
May 20, 2016
- Ono Ties Up with Univ. of Tokyo Venture for Antibody Drug
May 19, 2016
- Suzuken Outstrips Medipal in Drug Wholesaling Biz on Hep C Boom: Jiho Tally
May 19, 2016
- Takecab Most Heavily Pitched Drug for 3 Consecutive Months: Anterio
May 18, 2016
- Harvoni Tops Japan Yearly Sales Ranking Only 7 Months after Launch: IMS
May 18, 2016
- ASKA Dissolves Generic JV with Actavis
May 17, 2016
- Medipal to Set Up Subsidiary for Specialty Drugs
May 17, 2016
- Lilly, Kanazawa Medical Univ. Ink Research Deal on Diffuse-Type Gastric Cancer
May 17, 2016
- Top 8 Japan Drug Makers Relish 2.6-Fold Operating Profit Jump on Global Brands
May 17, 2016
- Chugai’s CellCept, Generic Versions Approved for Lupus Nephritis
May 17, 2016
- Nippon Kayaku Faces Damage Suit over Elplat Patent
May 17, 2016
- Santen Anticipates Continued Growth in Sales of Ikervis in Europe; 30% Overseas Sales Ratio an “Achievable Target”
May 17, 2016
- As Tagrisso Launch Nears, AZ Pushes Stringent Prerequisites for Facilities, Doctors to Ensure Safety
May 17, 2016
- Towa to Mull Over Distribution Dealing with Wholesalers
May 17, 2016
- Eisai Aims for 10% Rise in Japan Pharma Sales with Patented Products: CEO
May 16, 2016
- Eisai Posts Higher Profits despite Sales Dip, Global Brands Expand
May 16, 2016
- Kyorin Enthusiastic about Overcoming “Kipres Cliff,” Aiming for Over 50% Share with AG, 4 New Product Launches
May 16, 2016
- Ono to Erect New Opdivo Plant, Operational Launch Eyed for 2020
May 13, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…